Discover
QNCX
Quince Therapeutics, Inc.
29.48
2 x 21.17
2 x 35.46
bid
ask
+
2.47
9.14%
2 @ 07:30 PM
29.48 +0.00 (0.00%)
| Ytd | -95.60% | |
| 1y | -90.84% |
27.21
day range
29.89
16.00
52 week range
880.00
| Open | 27.21 | Prev Close | 27.01 | Low | 27.21 | High | 29.89 | Mkt Cap | 29.98M |
| Vol | 48.84K | Avg Vol | 30.30K | EPS | -210.84 | P/E | N/A | Forward P/E | -5.68 |
| Beta | 0.71 | Short Ratio | 2.27 | Inst. Own | 25.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 26.92 | 200-d Avg | 156.35 | 1yr Est | 9.00 |
| Income Statement | |||
| Operating Expenses | 79.78M | ||
| Research and Development Expense | 5.46M | ||
| Selling, General and Administrative Expense | 16.63M | ||
| Operating Income | -79.78M | ||
| Income Tax Expense | 75.00K | ||
| Net Income | -75.49M | ||
| Net Income Common Stock | -75.49M | ||
| Net Income Common Stock (USD) | -75.49M | ||
| Consolidated Income | -75.49M | ||
| Earnings per Basic Share | -12.31 | ||
| Earnings per Basic Share (USD) | -12.31 | ||
| Earnings per Diluted Share | -12.31 | ||
| Earning Before Interest & Taxes (EBIT) | -75.41M | ||
| Earning Before Interest & Taxes (USD) | -75.41M | ||
| Weighted Average Shares | 6.13M | ||
| Weighted Average Shares Diluted | 6.13M | ||
| Balance Sheet | |||
| Cash and Equivalents | 115.98M | ||
| Cash and Equivalents (USD) | 115.98M | ||
| Current Assets | 123.41M | ||
| Property, Plant & Equipment Net | 506.00K | ||
| Total Assets | 124.00M | ||
| Current Liabilities | 8.50M | ||
| Total Liabilities | 15.51M | ||
| Accumulated Retained Earnings (Deficit) | -500.03M | ||
| Accumulated Other Comprehensive Income | 4.26M | ||
| Shareholders Equity | -35.32M | ||
| Shareholders Equity (USD) | -35.32M | ||
| Assets Non-Current | 584.00K | ||
| Liabilities Non-Current | 7.01M | ||
| Trade and Non-Trade Payables | 4.64M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 41.00K | ||
| Net Cash Flow from Financing | 108.93M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 97.82M | ||
| Net Cash Flow - Business Acquisitions and Disposals | 8.00M | ||
| Issuance (Purchase) of Equity Shares | 5.29M | ||
| Net Cash Flow from Investing | 8.00M | ||
| Net Cash Flow from Operations | -18.89M | ||
| Effect of Exchange Rate Changes on Cash | -229.00K | ||
| Share Based Compensation | 12.09M | ||